Programmed death-ligand 1 (PD-L1) expression in various tumor types

PD-L1 Expression as a Predictive Biomarker in Cancer Immunotherapy

“…Based on an analysis of TNBC samples from the BIG 02-98 trial, a phase III adjuvant study comparing sequential versus concurrent docetaxel with anthracycline-based chemotherapy in breast cancer, a 10% increase in stromal TILs was associated with improved prognosis with a 15% reduction in relapse and a 17% reduction in death from TNBC (35,36). Expression of PD-L1 by IHC appears to be increased in TBNC relative to that in hormonedriven tumors, and the prognostic importance of TILs in TNBC make the PD-1/PD-L1 axis appealing as a therapeutic target (37,38). Recently, two phase 1 studies in metastatic TNBC have demonstrated preliminary signs of clinical activity.…”

“…A multitude of detection PD-L1 IHC antibodies have been utilized, including 28-8, 5H1, MIH1, and 405.9A11 (24,38). In addition, a number of proprietary companion diagnostics are being developed in this area ( Table 2).…”

Development of an Automated PD-L1 Immunohistochemistry (IHC) Assay for Non–Small Cell Lung Cancer

“…Multiple factors may contribute to the varied PD-L1 prevalence reported across these studies including differences in antibodies, assay methods, stages of the tumors, and treatments before sample collection [Bristol-Myers Squibb Inc. (BMS)/Dako presentation, 2013 Society for Immunotherapy of Cancer annual meeting]. 15 …”

Advanced Care Provider and Nursing Approach to Assessment and Management of Immunotherapy-Related Dermatologic Adverse Events

“…Together, they mediate a T-cell response, resulting in antitumor suppression (Genentech, 2016;Merck, 2016). In various cancers, such as melanoma, PD-L1 can be expressed on the tumor cell surface and can bind to the T-cell receptor PD-1 to manipulate the immune checkpoint pathway, suppressing T-cell tumor attack and promoting tumor growth advantage (Grosso et al, 2013;Hamid et al, 2013). These highly selective human monoclonal antibodies restore and potentiate T-cell antitumor response by inhibiting the nexus of PD-1 on T cells and PD-L1 expression on tumor cells-the PD-1 blockade pathway (Hamid et al, 2013;Harvey, 2014;Menzies & Long, 2013).…”